Repligen to Report First Quarter 2026 Financial Results
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will report first quarter 2026 financial results on Tuesday, May 5, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss results for the quarter ended March 31, 2026.
The call is accessible via toll-free dial-ins, meeting ID 931163466, and a live webcast on the company Investor Relations website; a replay will be archived afterwards.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RGEN
On the day this news was published, RGEN declined 5.04%, reflecting a notable negative market reaction. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $380M from the company's valuation, bringing the market cap to $7.16B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed action: TFX appeared in momentum scanners up 9.02%, while STVN was down 2.28%. Broader sector moves do not clearly align with RGEN’s modest 0.54% gain.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings date notice | Neutral | -0.4% | Set date and call details for Q4 and full-year 2025 results. |
Prior earnings-date notice saw a small negative move, suggesting limited standalone impact.
This announcement schedules Repligen’s Q1 2026 earnings release, continuing a pattern seen on Feb 10, 2026 when the company pre-announced its Q4 and full-year 2025 results, followed by a modest -0.36% move. Since then, Repligen has opened a European Training & Innovation Center in Breda and participated in multiple investor conferences, while previously reporting $738M 2025 revenue and issuing 2026 guidance. Today’s notice fits the company’s regular cadence of communications around quarterly reporting.
Historical Comparison
Past earnings-date news for RGEN led to a modest -0.36% move, indicating that scheduling announcements alone have historically produced limited stock reaction.
The company continues its standard practice of pre-announcing quarterly results dates and call logistics ahead of detailed earnings releases.
Market Pulse Summary
The stock moved -5.0% in the session following this news. A negative reaction to this scheduling update would contrast with the historically modest -0.36% move seen on a prior earnings-date notice. Such a decline could indicate broader concerns about the coming Q1 2026 release rather than the mechanics of the announcement itself. Earnings events can crystallize views on growth and margins, so positioning and risk management often become more cautious ahead of the call.
AI-generated analysis. Not financial advice.
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026.
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
